Novartis CTL019B2202; HM2015-14: A Phase II, single arm

Project: Research project

Project Details

Description

Novartis CTL019B2202; HM2015-14: A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
StatusActive
Effective start/end date9/22/159/21/21

Funding

  • NOVARTIS PHARMACEUTICALS CORPORATION

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.